

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert M. Jones et al.                      Art Unit : 1624  
Serial No. : 10/541,657                                      Examiner : Noble E. Jarrell  
Filed : March 3, 2006                                      Conf. No. : 4098  
Title : 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS  
MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND  
TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES  
AND HYPERGLYCEMIA

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CONSENT OF ARENA PHARMACEUTICALS, INC. UNDER 37 C.F.R. § 1.497(d)(3)**

Under 37 CFR §3.73(b), Arena Pharmaceuticals Inc., a corporation, ("the Assignee") certifies that it is the assignee of 100% of the right, title and interest in the patent application identified above by virtue of a chain of title from the inventors evidenced by the following documents:

- An assignment from the inventors to Arena Pharmaceuticals, Inc. The assignment was recorded in the Patent and Trademark Office at Reel 017254, Frame 0935 on March 6, 2006.

To the best of undersigned's knowledge and belief, title is in the Assignee identified above.

The undersigned, whose title is supplied below, is empowered to act on behalf of the Assignee.

The Assignee consents to the amendment of the inventorship of the above-referenced patent application, to add Mihai Azimioara as an inventor so as to name Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong, Vibha Dave and Mihai Azimioara as joint inventors.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Applicant : Robert M. Jones et al.  
Serial No. : 10/541,657  
Filed : March 3, 2006  
Page : 2 of 2

Attorney's Docket No.: 20750-  
0007US1 / 034.US5.PCT


Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Signed:

Arena Pharmaceuticals, Inc.

By:

Date:

  
Name: \_\_\_\_\_

06 April 2011

Title: \_\_\_\_\_

80104998.doc

**David L. Bradfute, Ph.D., J.D.**  
**Vice President & Assistant General Counsel,**  
**Intellectual Property & Tax**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert M. Jones et al.                      Art Unit : 1624  
Serial No. : 10/541,657                                      Examiner : Noble E. Jarrell  
Filed : March 3, 2006                                      Conf. No. : 4098  
Title : 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS  
MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND  
TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES  
AND HYPERGLYCEMIA

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**STATEMENT OF MIHAI D. AZIMIOARA UNDER 37 C.F.R. § 1.497(d)(1)**

I, Mihai D. Azimioara, declare as follows:


1. International Application PCT/US2004/001267 was filed naming as inventors Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong and Vibha Dave, rather than Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong, Vibha Dave and Mihai D. Azimioara.
2. Any error in inventorship in International Application PCT/US2004/001267 occurred without deceptive intention on my part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Signed:



Date:



**Mihai D. Azimioara**